We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

93 hedge funds and large institutions have $910M invested in Takeda Pharmaceutical in 2018 Q4 according to their latest regulatory filings, with 93 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more call options, than puts

Call options by funds: $7.49M | Put options by funds: $4.34M

6.8% more ownership

Funds ownership: 0% → 6.8% (+6.8%)

Holders
93
Holders Change
+93
Holders Change %
–
% of All Funds
2.07%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
93
Increased
–
Reduced
–
Closed
–
Calls
$7.49M
Puts
$4.34M
Net Calls
+$3.14M
Net Calls Change
+$3.14M

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$171M
2
Bank of America
Bank of America
North Carolina
+$116M
3
Citigroup
Citigroup
New York
+$111M
4
Goldman Sachs
Goldman Sachs
New York
+$86.2M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$63.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
51
Royal Bank of Canada
Ontario, Canada
$388K +$389K +23,047 New
LTFS
52
Ladenburg Thalmann Financial Services
Florida
$384K +$388K +23,000 New
QI
53
QS Investors
New York
$367K +$368K +21,792 New
Barclays
54
Barclays
United Kingdom
$362K +$363K +21,501 New
HC
55
Henshaw Capital
Massachusetts
$314K +$315K +18,650 New
Hudson Bay Capital Management
56
Hudson Bay Capital Management
Connecticut
$265K +$266K +15,748 New
SCM
57
Sterling Capital Management
North Carolina
$232K +$233K +13,821 New
US Bancorp
58
US Bancorp
Minnesota
$220K +$220K +13,050 New
QCG
59
Quadrant Capital Group
Ohio
$216K +$222K +13,142 New
Millennium Management
60
Millennium Management
New York
$215K +$216K +12,800 New
HAG
61
HighPoint Advisor Group
Illinois
$213K +$178K +10,563 New
Wells Fargo
62
Wells Fargo
California
$191K +$192K +11,368 New
AG
63
Advisor Group
Arizona
$114K +$115K +6,795 New
VAM
64
Velanne Asset Management
United Kingdom
$88K +$88.6K +5,250 New
TJHA
65
Thomas J. Herzfeld Advisors
Florida
$67K +$67.5K +4,000 New
TAIM
66
TD Ameritrade Investment Management
Nebraska
$45K +$45.5K +2,694 New
JWA
67
JFS Wealth Advisors
Pennsylvania
$43K +$43.1K +2,552 New
GRP
68
Global Retirement Partners
California
$35K +$35.4K +2,095 New
PCP
69
Proficio Capital Partners
Massachusetts
$34K +$34.3K +2,029 New
AAP
70
Arax Advisory Partners
Colorado
$20K +$20.3K +1,200 New
H
71
Hexavest
Quebec, Canada
$19K +$19.1K +1,134 New
FNBOSM
72
First National Bank of South Miami
Florida
$15K +$12.6K +745 New
FCA
73
FinTrust Capital Advisors
South Carolina
$13K +$12.6K +747 New
PCG
74
Private Capital Group
Connecticut
$10K +$9.72K +576 New
S
75
SignatureFD
Georgia
$9K +$8.95K +530 New
1 2
3
4

TAK Hedge Fund Activity: Q4 2018 in Review

93 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2018, worth a combined $910M.

Buyers outnumbered sellers: 93 funds opened new TAK positions and 0 closed out — a net gain of 93 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $171M.

  • 93 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2018, up from 0 in Q3 2018.
  • Funds reported $910M of Takeda Pharmaceutical stock for Q4 2018.
  • 93 funds opened new Takeda Pharmaceutical positions in Q4 2018 and 0 closed out, a net change of +93 holders.
  • The largest Takeda Pharmaceutical buyer in Q4 2018 was UBS Group, an estimated $171M added.

Based on aggregated 13F filings for Q4 2018.